Treats alcohol dependence. ANDA 207905, held by Chartwell. Naltrexone Hydrochloride.
As of Nov 16, 2026, ANDA 207905 (Naltrexone Hydrochloride), held by Chartwell, was first approved by FDA on Jul 21, 2017, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. Naltrexone hydrochloride tablets have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 21, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Naltrexone Hydrochloride50MG · tablet;oral | Naltrexone Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters